Patents Examined by Gollamudi S. Kishore
  • Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
    Patent number: 11324698
    Abstract: The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: May 10, 2022
    Assignee: VGSK Technologies, Inc.
    Inventors: Kameswari S. Konduri, Sandhya N. Nandedkar, Nejat Duzgunes, Pattisapu Ram Jogi Gangadharam
  • Nanoliposomal irinotecan for use in treating small cell lung cancer
    Patent number: 11318131
    Abstract: Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 3, 2022
    Inventors: Bambang Adiwijaya, Jonathan Basil Fitzgerald, Helen Lee
  • Method of treating carcinoma
    Patent number: 11304898
    Abstract: A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 19, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD
    Inventors: Wen Wee Ma, Alex Adjei, Lynne Bui, Ronald Harning, Ajay Khopade, Subhas Bhowmick, Natarajan Arulsudar, Narendra Lakkad
  • Compartmentalised gel matrix and method of production
    Patent number: 11304903
    Abstract: The invention provides a compartmentalised gel matrix comprising one or more compartments, wherein each compartment comprises a volume of hydrophobic medium and one or more aqueous droplets therein. The invention further provides a pharmaceutical formulation comprising a compartmentalised gel matrix according to the invention, a synthetic cell comprising a compartmentalised gel matrix according to the invention and a synthetic tissue comprising a compartmentalised gel matrix according to the invention.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: April 19, 2022
    Assignees: Oxford University Innovation Limited, Katholieke Universiteit Leuven
    Inventors: John Hagan Pryce Bayley, Kunwar Tanuj Sapra, Giovanni Maglia, Mariam Mohamed Abdelsattar Bayoumi
  • Nucleic acid-containing lipid nanoparticles
    Patent number: 11298326
    Abstract: The present invention provides nucleic acid-containing lipid nanoparticles containing a lipid (lipid A) which has a hydrophilic unit having a single quaternary ammonium group, and three independent, optionally substituted hydrocarbon groups, a lipid derivative or fatty acid derivative of a water-soluble polymer, and a nucleic acid.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: April 12, 2022
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Kentaro Hatanaka, Nobuhiro Yagi, Takeshi Kuboyama, Kaori Yagi, Shintaro Hosoe
  • Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
    Patent number: 11291644
    Abstract: The described invention provides methods for treating pulmonary cancer in a subject, by administering to the subject by inhalation a composition of inhalational lipid cisplatin (ILC) comprising a lipid-complexed cisplatin.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: April 5, 2022
    Assignee: ELEISON PHARMACEUTICALS, LLC
    Inventors: Forrest H. Anthony, Matthew M. Parris, Edwin J. Thomas, Guangtao Zhang
  • Ophthalmic formulations providing durable ocular lubrication
    Patent number: 11278493
    Abstract: This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: March 22, 2022
    Assignee: ETERNATEAR, INC.
    Inventors: Timothy R. Willis, Ralph P. Stone
  • PEGylated liposomes and methods of use
    Patent number: 11266602
    Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: March 8, 2022
    Assignee: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Christopher B. Fox, Susan S. Lin, Darrick Carter, Neal Van Hoeven, Mayuresh M. Abhyankar, William A. Petri
  • Nanosome formulations of aprepitant and methods and applications thereof
    Patent number: 11260028
    Abstract: Disclosed herein are pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. The pharmaceutical formulations are stable and ready-to-use liposomes for the treatment of emesis and are particularly useful for treatment of chemotherapy or surgery-induced nausea and vomiting. Methods of preparation of the aprepitant formulations are also provided.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: March 1, 2022
    Assignee: ForDoz Pharma Corp.
    Inventors: Sydney Ugwu, Xin He, Zengli Fu, Xin Teng, Ming Ji
  • Engineered liposomes as cancer-targeted therapeutics
    Patent number: 11260132
    Abstract: The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 1, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Peng Guo, Jiang Yang, Debra Auguste, Daxing Liu
  • Process for preparing a powdered composition
    Patent number: 11260001
    Abstract: The present disclosure relates to the field of delivery systems. More particularly, the present disclosure relates to a process for preparing a powdered composition including granules. The granules include at least one active substance present in an encapsulated form and in a non-encapsulated form. They are obtained by drying a mixture including an aqueous phase of a water-soluble polymer, a Pickering emulsion including a non-encapsulated active substance and a microcapsule slurry including an encapsulated active substance that can differ or being the same as the non-encapsulated substance. The disclosure further relates to granules obtained by the process and to products containing them.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 1, 2022
    Assignee: FIRMENICH SA
    Inventors: Pierre-Etienne Bouquerand, Pascal Beaussoubre, Wolfgang Fieber, François Meyer
  • Long-circulating liposome modified with c(RGD-ACP-K)
    Patent number: 11260068
    Abstract: The present invention relates to a long-circulating liposome modified with c(RGD-ACP-K). The present invention pertains to the field of pharmaceutical preparations, in particular to the field of targeted pharmaceutical preparations. More specifically, the present invention relates to a long-circulating liposome, the surface of the liposome being modified with c(RGD-ACP-K), and the liposome comprising doxorubicin or a pharmaceutically acceptable salt thereof such as doxorubicin hydrochloride as an anti-cancer active agent. The long-circulating liposome can targetedly deliver the anti-cancer active agent into tumor neovascular endothelial cells and tumor cells and can prolong the circulation time of the liposome in vivo, thereby enhancing the therapeutic effect of anti-tumor medicaments.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 1, 2022
    Assignee: BEIJING GREATSUN BTO-PHARM. TECH. CO., LTD
    Inventors: Qiang Zhang, Cuishuan Wu, Yue Su, Changjin Lee, Guanghua Cui
  • Serial filtration to generate small cholesterol-containing liposomes
    Patent number: 11246832
    Abstract: The present invention provides methods and systems for producing liposomes by filtration. The methods include passing a heated lipid suspension through a filter assembly comprising two or more filters connected in series, wherein an orifice is disposed between adjacent filters. The methods and systems can produce liposomes having an average diameter that is less than half the diameter of the filter pores. Further, the methods and systems can produce liposomes with <100 nm average diameter, even when the liposomes comprise at least 30% sterol.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: February 15, 2022
    Assignee: Verily Life Sciences LLC
    Inventors: Stephen Morton, Zach Scott
  • Medical use of sPLA2 hydrolysable liposomes
    Patent number: 11207269
    Abstract: The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: December 28, 2021
    Assignee: BIO-BEDST APS
    Inventors: Morten Just Petersen, Fredrik Melander, Anders Falk Vikbjerg, Sune Allan Petersen, Mogens Winkel Madsen
  • Liposomes for drug delivery and methods for preparation thereof
    Patent number: 11173178
    Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: November 16, 2021
    Assignee: LiPlasome Pharma ApS
    Inventors: Anders Falk Vikbjerg, Sune Allan Petersen, Fredrik Melander, Jonas Rosager Henriksen, Kent Jørgensen
  • Stable formulations of lipids and liposomes
    Patent number: 11173120
    Abstract: The present invention related to aqueous lipid and/or liposome formulations with an increased chemical stability, to methods of preparing such aqueous formulations as well as to kits comprising them. The present invention further relates to methods of preparing lipid-based pharmaceutical compositions, to pharmaceutical compositions prepared by such methods and to methods of chemically stabilizing aqueous lipid and/or liposome formulations.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: November 16, 2021
    Assignee: BioNTech RNA Pharmaceuticals GmbH
    Inventors: Heinrich Haas, Isaac Hernan Esparza Borquez
  • Tumor therapeutic agent and kit containing gemcitabine liposome composition
    Patent number: 11166914
    Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: November 9, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Tsukasa Kitahashi, Shinji Mima, Takeshi Matsumoto, Takahiro Sekiguchi, Mikinaga Mori
  • Tumor therapeutic agent and kit containing gemcitabine liposome composition
    Patent number: 11166913
    Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 9, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Tsukasa Kitahashi, Shinji Mima, Takeshi Matsumoto, Takahiro Sekiguchi, Mikinaga Mori
  • Amphiphilic polymer
    Patent number: 11160755
    Abstract: The present application relates to an amphiphilic polymer and a method for producing the same. The present application also relates to micelles comprising the amphiphilic polymer and a method for producing the same. The amphiphilic polymer of the present application can have excellent dispersion properties while effectively encapsulating the drug.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 2, 2021
    Assignees: LG Chem, Ltd., LG Household & Health Care Ltd.
    Inventors: Su Jeong Kim, Jeong Ae Yoon, Sun Hwa Lee, Woo Sun Shim, Sung Soo Yoon, Chang Hwan Ju, Kyung Oh Kim, Jung A Kim, Nae Gyu Kang
  • Silica microcapsules and methods of preparing same
    Patent number: 11160761
    Abstract: Disclosed is a microcapsule containing: (i) a microcapsule core having an active material, and (ii) a microcapsule wall formed of a first polymer and second polymer. The first polymer is a sol-gel polymer. The second polymer is gum arabic, purity gum ultra, gelatin, chitosan, xanthan gum, plant gum, carboxymethyl cellulose, sodium carboxymethyl guar gum, or a combination thereof. The weight ratio between the first and second polymer is 1:10 to 10:1. Also disclosed are processes for preparing the microcapsule and uses of the microcapsules in consumer products.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 2, 2021
    Assignee: International Flavors & Fragrances Inc.
    Inventors: John Brahms, Ronald Gabbard, Feng Geng, Julie Ann Wieland, Li Xu, Lewis Michael Popplewell